BioCentury
ARTICLE | Clinical News

HuMax-EGFr: Preliminary Phase I/II data

October 11, 2004 7:00 AM UTC

Preliminary data from a Phase I/II trial in 24 patients showed that HuMax-EGFr was well tolerated up to maximal dose of 8 mg/kg. GEN said it will expand the study to include up to 10 additional patien...